ObjectiveTo determine the prevalence of neuropsychological outcomes in individuals with type 1 diabetes compared to individuals with type 2 diabetes or without diabetes, and to evaluate the association of diabetes status and microvascular/macrovascular complications with neuropsychological outcomes.Patients and MethodsWe used a nationally representative healthcare claims database of privately insured individuals (1/1/2001-12/31/2018) to identify individuals with type 1 diabetes. Propensity score matching was used as a quasi-randomization technique to match type 1 diabetes individuals to type 2 diabetes individuals and controls. Diabetes status, microvascular/macrovascular complications (retinopathy, neuropathy, nephropathy, stroke, myocardial infarction, peripheral vascular disease, amputations), and neuropsychological outcomes (mental health, cognitive, chronic pain, addiction, sleep disorders) were defined using ICD-9/10 codes. Logistic regression determined associations between diabetes status, microvascular/macrovascular complications, and neuropsychological outcomes.ResultsWe identified 184,765 type 1 diabetes individuals matched to 524,602 type 2 diabetes individuals and 522,768 controls. With the exception of cognitive disorders, type 2 diabetes individuals had the highest prevalence of neuropsychological outcomes, followed by type 1 diabetes, and controls. After adjusting for the presence of microvascular/macrovascular complications, type 1 diabetes was not significantly associated with a higher risk of neuropsychological outcomes; however, type 2 diabetes remained associated with mental health, cognitive, and sleep disorders. The presence of microvascular/macrovascular complications was independently associated with each neuropsychological outcome regardless of diabetes status.ConclusionMicrovascular/macrovascular complications are associated with a high risk of neuropsychological outcomes regardless of diabetes status. Therefore, preventing microvascular and macrovascular complications will likely help reduce the likelihood of neuropsychological outcomes either as the result of similar pathophysiologic processes or by preventing the direct and indirect consequences of these complications. For individuals with type 2 diabetes, risk factors beyond complications (such as obesity) likely contribute to neuropsychological outcomes.

No abstract

Objective: To describe and compare healthcare costs and utilization for persons with type 1 diabetes (T1D), type 2 diabetes (T2D), and those without diabetes. Methods: Using a nationally representative healthcare claims database, we identified matched persons with T1D, T2D, and those without diabetes using a propensity score quasi-randomization technique. In each year between 2009-2018, we summed costs (total and out-of-pocket) and utilization for all healthcare services and those specific to medications, diabetes-related supplies, visits to healthcare providers, hospitalizations, and emergency room (ER) visits. Costs and utilization were scaled using total patient follow-up in each year. Results: In 2018, we found that out-of-pocket costs and total costs were highest for persons with T1D (out-of-pocket: $950, total: $10,626), followed by persons with T2D (out-of-pocket: $670, total: $7,516), and persons without diabetes (out-of-pocket: $447, total: $4,483). Medication costs made up the largest proportion of out-of-pocket costs regardless of diabetes status (T1D: 78.2%, T2D: 76.2%, control: 70.5%). From 2009-2018, utilization of hospitalizations (T1D: +23.7%, T2D: +17.3%, controls: +22.0%) and ER visits (T1D: +54.9%, T2D: +56.0%, controls: +50.1%) increased regardless of diabetes status, and use of diabetes-related supplies (+22.1%) were increasing for persons with T1D. Conclusions: Given the substantial out-of-pocket costs for people with diabetes, especially for those with T1D, providers should screen all persons with diabetes for financial toxicity (i.e., wide-ranging problems stemming from these healthcare costs). In addition, policies that aim to lower out-of-pocket costs of cost-effective diabetes related healthcare are needed with a focus on medication related costs. Disclosure E.L.Reynolds: None. K.R.Mizokami-stout: None. N.Putnam: None. M.Banerjee: None. D.Albright: None. J.M.Lee: Advisory Panel; GoodRx, Consultant; Tandem Diabetes Care, Inc. R.Busui: Board Member; American Diabetes Association, Consultant; Averitas Pharma, Inc., Lexicon Pharmaceuticals, Inc., Nevro Corp., Novo Nordisk, Roche Diagnostics, Procter & Gamble, Research Support; Novo Nordisk, Medtronic, National Institutes of Health. E.L.Feldman: None. B.C.Callaghan: None. Funding National Institutes of Health (K99DK129785 to E.V.L.), (1K23DK13129601A1 to K.R.M-S.), (D300P30, 12959224, UH3HD087979, UH3HD087979-04S1 to J.M.L.), (R01DK115687 to B.C.C.), (R01DK129320, R01DK107956, R01DK130913 to E.L.F.); National Institute of Diabetes